Bullock A, Kaul I, Li S, et al. - Researchers focused on the impacts of zuranolone (SAGE-217), which is an investigational oral neuroactive steroid (NAS) gamma-aminobutyric acid A (GABA _A) receptor–positive allosteric modulator (PAM), mainly on tremor symptoms in patients suffering from Parkinson disease (PD) in this current open-label study. The patients (n = 14, mean age, 65.1 years; mean time since PD diagnosis, 9 years) were given zuranolone capsules (20 to 30 mg) for 7 days. From baseline, an improvement by 40% in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II/III Tremor Score was evident on Day 8. Also, improvements were observed in the motor score, and nonmotor experiences of daily living, and motor experiences of daily living scores (MDS-UPDRS Parts I and II, respectively) on Day 8. There were no serious adverse events, and none of the patients discontinued treatment. Findings demonstrated the general good tolerability of zuranolone as well as its efficacy in improving tremor symptoms in patients with PD who were on stable doses of concurrent dopaminergic agents. Thus, further inquiry of NAS GABA _A receptor PAMs as adjunctive therapy for tremor in PD patients is supported.